...
首页> 外文期刊>Travel medicine and infectious disease >Effectiveness in prevention of travellers' diarrhoea by an oral cholera vaccine WC/rBS
【24h】

Effectiveness in prevention of travellers' diarrhoea by an oral cholera vaccine WC/rBS

机译:口服霍乱疫苗WC / rBS预防旅行者腹泻的功效

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: To investigate the effectiveness of an oral cholera vaccine (Dukoral~R) in preventing travellers' diarrhoea. Material and methods: A retrospective study was conducted among travellers who had attended the International Vaccination Centre in Malaga, Spain, before starting their journey. A telephone interview was undertaken from November 2005 to January 2006 after the travellers had returned from their trip. The relationship between vaccination with Dukoral~R and travellers' diarrhoea was analysed by means of a logistic regression model, adjusting for possible confounding variables (traveller's age, duration of trip and region visited). Results: The overall incidence of diarrhoea in vaccinated travellers was 23% compared with 40% in non-vaccinated travellers (historical control group) (p = 0.004). Short episodes of diarrhoea were reported in significantly more travellers of the vaccinated group than of the non-vaccinated group (average duration of diarrhoea 2.21 days versus 3.97 days, p = 0.005). The incidence of diarrhoea was significantly lower among vaccinated than non-vaccinated travellers who went to Africa for less than 3 weeks (16% versus 48%, p = 0.002) or India and South East Asia (19% versus 50%, p =0.052) for more than 3 weeks. No adverse events were reported in the group of vaccinated travellers. Discussion: Vaccination reduced the risk of travellers' diarrhoea by 43%; possibly due to the protective effect of the oral vaccine Dukoral~R against travellers' diarrhoea caused by enterotoxigenic Escherichia coli (ETEC) or cholera. The efficacy of vaccination increased after adjusting for confounding factors, being modified by traveller age (under 30 years, or 45 years and older the protective effect of the vaccine is 4.8 greater, 95% confidence interval (Cl): 2.1-10.7).
机译:目的:探讨口服霍乱疫苗(Dukoral〜R)预防旅行者腹泻的有效性。材料和方法:在开始旅程之前,对在西班牙马拉加参加国际疫苗接种中心的旅行者进行了回顾性研究。旅行者从旅行中回来后,于2005年11月至2006年1月进行了电话采访。通过逻辑回归模型分析了接种Dukoral_R疫苗与旅行者腹泻之间的关系,并调整了可能的混杂变量(旅行者的年龄,旅行时间和就诊区域)。结果:接种疫苗的旅行者的腹泻总发生率为23%,而未接种疫苗的旅行者(历史对照组)的总体腹泻发生率为40%(p = 0.004)。据报告,接种疫苗组的旅行者中有短时间的腹泻发生率明显高于未接种疫苗的组(平均腹泻时间为2.21天对3.97天,p = 0.005)。在非洲旅行少于3周(16%比48%,p = 0.002)或印度和东南亚(19%比50%,p = 0.052)的疫苗接种者中,腹泻的发生率明显低于未接种疫苗的旅行者。 )超过3周。接种疫苗的旅行者中没有不良反应的报道。讨论:接种疫苗使旅行者腹泻的风险降低了43%;可能是由于口服疫苗Dukoral_R对由产肠毒素的大肠杆菌(ETEC)或霍乱引起的旅行者腹泻的保护作用。调整混杂因素后,疫苗的功效有所提高,并因旅行者的年龄(低于30岁或45岁及以上)而改变,疫苗的保护作用更高4.8,95%置信区间(Cl):2.1-10.7)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号